Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study to Test the Safety and Efficacy of Metformin, Dasatinib, Rapamycin and Nutritional Supplements in Reducing Clinical Measures of Aging in Older Adults
NCT04994561Phase 1Withdrawn
- Sponsor
- Vitality in Aging Research Group
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of metformin, dasatinib, sirolimus, quercetin, fisetin and 3 more in aging, sponsored by Vitality in Aging Research Group. Primary endpoints: Incidence of treatment-emergent adverse events at Day 532, Visceral adipose tissue fat tissue volume at Day 502 and 4 more. Planned start Jun 2022; status: withdrawn.
02
Drugs
metformindasatinibsirolimusquercetinfisetin
03
Conditions
aging
Beyond the preview
Go deeper on NCT04994561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994561.